Please assess the completion status of the following clinical trial:

Trial Title: Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of atrial fibrillation since no longer than 48 hours~* Age 18 - 90 years~Exclusion Criteria:~* Need for immediate electrical cardioversion due to hemodynamic instability (hypotension: systolic blood pressure \< 100 mmHg, dyspnea, loss of consciousness, unstable angina)~* Moderate to severe heart failure (NYHA III/IV) and patients with previously documented left ventricular ejection fraction (LVEF) ≤ 35%~* History or signs of acute coronary syndromes (acute myocardial infarction, unstable angina) within the last 30 days~* Resting ventricular rate \< 80 beats per minute without pace maker back-up~* QT interval of \> 440 milliseconds~* Wolff-Parkinson-White (WPW) syndrome~* History of Torsade de pointes arrhythmias or other polymorphic ventricular tachycardias~* Signs of thyreotoxicosis~* Sick Sinus Syndrome or atrioventricular block greater than first degree~* Severe valvular heart disease, clinically meaningful hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis~* Serious disorders of the hepatic, renal (Creatinine \> 2.5mg/dl), pulmonary, gastrointestinal, hematologic or central nervous system and serious psychiatric disorders~* Abnormal serum electrolytes despite adequate therapy (especially potassium \<3.5 mmol/l or \> 5.5 mmol/l)~* Intravenous use of other Class I or III antiarrythmic drugs within 4 hours of study drug application~* Pregnancy (a β-HCG test will be performed in all female subjects apart from women \> 50 years and with amenorrhea for at least 12 month (absence of other causes of amenorrhoea)~* Known hypersensitivity to study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vernakalant (Type: ACTIVE_COMPARATOR): Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
- Ibutilide (Type: ACTIVE_COMPARATOR): Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).